|

Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer

RECRUITINGSponsored by Women's Hospital School Of Medicine Zhejiang University
Actively Recruiting
SponsorWomen's Hospital School Of Medicine Zhejiang University
Started2023-10-26
Est. completion2026-09-10
Eligibility
Age18 Years – 75 Years
SexFEMALE
View on ClinicalTrials.gov →

NCT06019923

Summary

Ovarian cancer is a highly lethal gynecological malignancy, often diagnosed at an advanced stage, with high rates of recurrence within 1-2 years after frontline treatment. Current guidelines recommend monitoring tumor markers CA125 and HE4 for disease progression, but these markers may not detect recurrence or disease progression when their levels are below the detection limit. Therefore, there is a need to identify new prognostic biomarkers and monitor their dynamic changes for effective risk stratification and personalized treatment in patients with ovarian cancer

Eligibility

Age: 18 Years – 75 YearsSex: FEMALE
Inclusion Criteria:

* Age between 18 and 75 years;
* Pathological diagnosis of high-grade serous ovarian cancer;
* Newly diagnosed ovarian cancer case without prior neoadjuvant therapy.

Exclusion Criteria:

* Non-primary (recurrent) patients;
* Ovarian cancer patients who have not undergone surgical treatment;
* Patients with a history of other malignancies.

Conditions2

CancerOvarian Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.